This study aimed to explore the evolutionary trajectory of 3 DBZDs—etizolam, pyrazolam, and flubromazepam—from their pre-regulation prominence to the present day. to accomplish this intention, our research layout included a multifaceted approach to extract beneficial insights from rising drug marketplaces. It encompassed an extensive quantitati